Uniplan Investment Counsel’s iRadimed IRMD Stock Holding History

Uniplan Investment Counsel’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.35M	Buy	66,402 +4,261	+7%	+$388K	0.6%	52
2026 Q1	$5.98M	Sell	62,141 -3,554	-5%	-$355K	0.61%	44
2025 Q4	$6.39M	Sell	65,695 -11,619	-15%	-$997K	0.64%	42
2025 Q3	$5.5M	Sell	77,314 -3,033	-4%	-$202K	0.54%	48
2025 Q2	$4.8M	Buy	80,347 +31,620	+65%	+$1.73M	0.49%	54
2025 Q1	$2.56M	Buy	48,727 +16,187	+50%	+$909K	0.25%	95
2024 Q4	$1.79M	Buy	+32,540	New	+$1.71M	0.17%	106

Other funds holding IRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NTCM

Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Uniplan Investment Counsel's IRMD Position: Q2 2026 in Review

Uniplan Investment Counsel increased its iRadimed (IRMD) stake by 6.9% in Q2 2026, buying an estimated $388K and bringing the position to 66,402 shares worth $6.35M. The position accounts for 0.6% of the portfolio, ranked #52.

Uniplan Investment Counsel first reported a position in IRMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.39M in Q4 2025. 214 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

Uniplan Investment Counsel held 66,402 shares of iRadimed worth $6.35M as of Q2 2026.
Uniplan Investment Counsel bought 4,261 iRadimed shares in Q2 2026, an estimated $388K.
iRadimed made up 0.6% of Uniplan Investment Counsel's portfolio in Q2 2026, its #52 holding.
Uniplan Investment Counsel first reported a position in iRadimed in Q4 2024 and has held it in 7 quarters since.
Uniplan Investment Counsel's iRadimed position peaked at $6.39M in Q4 2025.
214 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.